EvanYa-WenYuMD

Oncology • Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Join to view full profile

Dr. Yu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yu's full profile

Already have an account?

Office
Ambulatory Clinic
825 Eastlake Avenue East
Seattle, WA 98109
Phone+1 206-288-1000

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2001
University of Washington School of MedicineClass of 1998

Certifications & Licensure

MT State Medical License 2021 - 2025
WA State Medical License 2004 - 2025
MA State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone Start of enrollment: 2005 Dec 01
Completed
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer Start of enrollment: 2006 Dec 01
Completed
Phase 2
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases Start of enrollment: 2009 Sep 01
Completed
Phase 2
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Start of enrollment: 2010 Dec 01
Completed
Phase 2
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel Start of enrollment: 2010 Jul 12
Terminated
Phase 2
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2013 Sep 10
Completed
Phase 2
Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer Start of enrollment: 2015 Dec 01
Withdrawn
Not Applicable
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Start of enrollment: 2019 Jun 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither, Gianluca Del Conte, Miguel Martín
Clinical Cancer Research. 2024-12-16
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer ReceivingLu-PSMA-617.
Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, Todd Yezefski, Michael C Haffner
Journal of Nuclear Medicine. 2024-12-03
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu
Clinical Cancer Research. 2024-12-02

Journal Articles

Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference
Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology
Undetectable Prostate‐Specific Antigen After Short‐Course Androgen Deprivation Therapy for Biochemically Recurrent Patients Correlates with Metastasis‐Free Survival an...
Heather H Cheng, Jonathan T Wingate, Evan Y Yu, The Prostate

Lectures

A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carci...
2019 ASCO Annual Meeting - 6/1/2019
Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYN...
2019 ASCO Annual Meeting - 6/1/2019
Targeted Therapies in Advanced Urothelial Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Kineta Appoints Internationally-Renowned Clinical Immuno-Oncology Experts to Its Scientific Advisory BoardMarch 1st, 2023
What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 2May 18th, 2022
What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 1May 18th, 2022
Join now to see all